[go: up one dir, main page]

JP2018122081A - Microneedle and manufacturing method thereof - Google Patents

Microneedle and manufacturing method thereof Download PDF

Info

Publication number
JP2018122081A
JP2018122081A JP2017235882A JP2017235882A JP2018122081A JP 2018122081 A JP2018122081 A JP 2018122081A JP 2017235882 A JP2017235882 A JP 2017235882A JP 2017235882 A JP2017235882 A JP 2017235882A JP 2018122081 A JP2018122081 A JP 2018122081A
Authority
JP
Japan
Prior art keywords
tip
microneedle
base
drug
shoulder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017235882A
Other languages
Japanese (ja)
Other versions
JP6681378B2 (en
Inventor
圭祐 寺田
Keisuke Terada
圭祐 寺田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tera Stone Co Ltd
Original Assignee
Tera Stone Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tera Stone Co Ltd filed Critical Tera Stone Co Ltd
Priority to JP2017235882A priority Critical patent/JP6681378B2/en
Publication of JP2018122081A publication Critical patent/JP2018122081A/en
Application granted granted Critical
Publication of JP6681378B2 publication Critical patent/JP6681378B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0053Methods for producing microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

【課題】皮膚に穿刺した際に、先端部が表皮を貫通して真皮に到達し、真皮内に正確に一定量の薬物を供給することの出来るマイクロニードルとその製造方法を提供する。【解決手段】鋭利な先端を有する円錐形又は角錐形の先端部102と、円錐台形又は角錐台形の基台部104とを備え、先端部102と基台部104とは、基台部104の肩部106において段差を有して結合されたマイクロニードル100であって、先端部位102と基台部位104異なる材質で構成され、先端部102の構成材料にのみ一定量の薬物を含有させている。マイクロニードル100が皮膚に穿刺されると、先端部102と基台部104とが結合部で分離され、先端部102のみが皮膚内に残存することとなり、一定量の薬物を正確に生体に投与できる。【選択図】図1Disclosed is a microneedle capable of accurately supplying a constant amount of drug into the dermis by providing a tip that penetrates the epidermis and reaches the dermis when the skin is punctured. A cone-shaped or pyramid-shaped tip portion having a sharp tip and a truncated cone-shaped or truncated pyramid-shaped base portion 104 are provided, and the tip portion 102 and the base portion 104 are formed of the base portion 104. A microneedle 100 coupled with a step at the shoulder 106, which is composed of a material different from the distal end portion 102 and the base portion 104, and only a constituent material of the distal end portion 102 contains a certain amount of drug. . When the microneedle 100 is punctured into the skin, the distal end portion 102 and the base portion 104 are separated at the joint portion, and only the distal end portion 102 remains in the skin, and a certain amount of drug is accurately administered to the living body. it can. [Selection] Figure 1

Description

本発明は、マイクロニードルとその製造方法に係り、特に、皮膚の真皮に正確に一定量の薬物を注入することが可能なマイクロニードルとその製造方法に関する。   The present invention relates to a microneedle and a method for manufacturing the microneedle, and more particularly, to a microneedle capable of accurately injecting a predetermined amount of drug into the dermis of the skin and a method for manufacturing the microneedle.

塗布や、注射による生体への薬物投与に替えて、マイクロニードルによる薬物投与がこれまで多く提案されている。例えば、特許文献1や特許文献2では、マイクロニードルの先端部近傍の表面に薬物を付着(コーティング)する方法が提案されている。
特許文献1で提案されている方法では、付着した薬物が皮膚に穿刺される際に剥がれ落ちることはないとしても、薬物の付着量を正確にコントロールすることが困難であるという欠点を有している。
また、特許文献2で提案されている方法では、付着量は正確にコントロールすることが出来たとしても、皮膚に穿刺された状態で付着された薬物の何パーセントが生体に吸収されるかが必ずしも正確に予測できないという欠点を有している。
Many drug administrations using microneedles have been proposed in place of application and drug administration to living bodies by injection. For example, Patent Document 1 and Patent Document 2 propose a method of attaching (coating) a drug to the surface near the tip of the microneedle.
The method proposed in Patent Document 1 has a drawback that it is difficult to accurately control the amount of the adhered drug even if the adhered drug does not peel off when puncturing the skin. Yes.
Further, in the method proposed in Patent Document 2, even if the amount of adhesion can be accurately controlled, it is not always possible to determine what percentage of the drug adhered in the state of being punctured on the skin is absorbed by the living body. It has the disadvantage that it cannot be predicted accurately.

非特許文献1や非特許文献2では、マイクロニードルの材質をヒアルロン酸などの生体内溶解材料とし、この材料中にインスリンなどの薬物を含有させて皮膚に穿刺することを開示しているが、やはり生体に吸収される有効薬物の量を正確にコントロールすることが出来ないという欠点を有している。   Non-Patent Document 1 and Non-Patent Document 2 disclose that the material of the microneedle is an in-vivo-dissolving material such as hyaluronic acid, and punctures the skin by containing a drug such as insulin in the material. Again, there is a drawback that the amount of effective drug absorbed by the living body cannot be accurately controlled.

特開2011−224308号公報JP 2011-224308 A WO2008/139648A1WO2008 / 139648A1

山本昌“ペプチド・タンパク性医薬品の経粘膜透過促進”薬剤学Vol.74,No.1(2014)Masaru Yamamoto “Promoting transmucosal penetration of peptide and protein drugs” Pharmacology Vol. 1 (2014) 勝見英正等,“マイクロニードルを用いたペプチド・タンパク性医薬品の次世代型経皮吸収製剤の開発”YAKUGAKU ZASSHI 134(1)63−67(2014)Hidemasa Katsumi et al., “Development of next-generation transdermal drug delivery for peptide and protein drugs using microneedles” YAKUGAKU ZASSHI 134 (1) 63-67 (2014)

本発明は上述した従来技術の問題点に鑑み提案されたもので、皮膚に穿刺した際に先端部が表皮を貫通して真皮に到達し、真皮内に正確に一定量の薬物を供給することの出来るマイクロニードルを提供することを目的とする。   The present invention has been proposed in view of the above-mentioned problems of the prior art, and when a skin is punctured, the distal end portion penetrates the epidermis to reach the dermis and supplies a certain amount of drug accurately into the dermis. An object of the present invention is to provide a microneedle that can be used.

本発明のマイクロニードルは、鋭利な先端を有する円錐形又は角錐形の先端部と円錐台形又は角錐台形の基台部とを備え、先端部と基台部とは、基台部の肩部において段差を有して結合されたマイクロニードルにおいて、先端部の先端から肩部までの高さと基台部の高さとは、マイクロニードルを先端から皮膚に穿刺した際に、先端部はすべて真皮内にとどまり、基台部は、少なくとも肩部が角質層と真皮との境界まで侵入するのに十分な寸法に設計され、先端部と基台部とはその構成材料の材質を異にし、先端部の構成材料にのみ一定量の薬物を含有させたことを特徴とする。
また、薬物がペプチド・タンパク性医薬品であることを特徴とする。
また、先端部の先端角度と、基台部の先端側端部の角度とが共に14°未満に設定されていることを特徴とする。
さらに、肩部において、先端部と基台部とが容易に切離され、先端部のみを皮膚の真皮内に残留させることを特徴とする。
The microneedle of the present invention includes a cone-shaped or pyramid-shaped distal end portion having a sharp tip and a truncated cone-shaped or truncated pyramid-shaped base portion, and the distal end portion and the base portion are located at the shoulder portion of the base portion. In the microneedle connected with a step, the height from the tip of the tip to the shoulder and the height of the base are the same as when the microneedle is punctured from the tip into the skin. The base part is designed to have a dimension sufficient to allow at least the shoulder part to penetrate to the boundary between the stratum corneum and the dermis, and the tip part and the base part are made of different constituent materials. It is characterized in that a certain amount of drug is contained only in the constituent materials.
The drug is a peptide / protein drug.
In addition, the tip angle of the tip and the angle of the tip side end of the base part are both set to be less than 14 °.
Furthermore, in the shoulder portion, the distal end portion and the base portion are easily separated, and only the distal end portion remains in the dermis of the skin.

本発明のマイクロニードルの製造方法は、
a:鋳型材料への直接レーザエッチング又はフォトリソグラフィーを用いた食刻技術により、先端側に位置する先端部位と基台側に位置する基台部位とを備え、
先端部位と基台部位とは、基台部位の肩部において段差を有して結合されたマイクロニードルパターンの反転形状を有する鋳型を作製する工程と;
b:先端部位に一定量の薬物を含有した液状の第1構成材料で肩部に到達するまで充填し、所定時間放置して固化を開始させる工程と;
c:基台部位に第1構成材料とは材質が異なる液状の第2構成材料を充填し、所定時間放置し、先端部位と基台部位とを肩部において結合させる工程と;
d:第1構成材料と第2構成材料とを固化させてマイクロニードルを形成する工程と;
e:形成されたマイクロニードルを鋳型から取り出す工程と;
を具備したことを特徴とする。
The method for producing the microneedle of the present invention comprises:
a: By a direct laser etching on the mold material or an etching technique using photolithography, a tip part located on the tip side and a base part located on the base side are provided,
A step of producing a mold having an inverted shape of a microneedle pattern in which the tip portion and the base portion are joined with a step at the shoulder portion of the base portion;
b: a step of filling the tip part with a liquid first constituent material containing a certain amount of drug until it reaches the shoulder and allowing it to stand for a predetermined time to start solidification;
c: filling the base part with a liquid second constituent material that is different from the first constituent material, leaving the base part for a predetermined time, and joining the tip part and the base part at the shoulder;
d: a step of solidifying the first constituent material and the second constituent material to form a microneedle;
e: removing the formed microneedle from the mold;
It is characterized by comprising.

本発明のマイクロニードルによれば、先端部位と基台部位とで構成材料の材質を異ならせたことにより、皮膚に穿刺された後に先端部と基台部とが結合部で分離され易く、先端部のみを皮膚内に残存させることができる。
このため、先端部位のみに薬物を含有させておけば、薬物を正確に一定量生体に投与できる。
According to the microneedle of the present invention, the tip portion and the base portion are made of different materials, so that the tip portion and the base portion are easily separated at the joint portion after being punctured into the skin. Only the part can remain in the skin.
For this reason, if a drug is contained only in the tip part, the drug can be accurately administered to a living body.

本発明の実施形態に係るマイクロニードルの構成図。The block diagram of the microneedle which concerns on embodiment of this invention. 図1に示すマイクロニードルが皮膚に穿刺された状態を示す説明図。Explanatory drawing which shows the state by which the microneedle shown in FIG. 1 was punctured by skin. 図1に示すマイクロニードルが皮膚から抜き取られた状態を示す説明図。Explanatory drawing which shows the state by which the microneedle shown in FIG. 1 was extracted from skin. 実施形態に係るマイクロニードルの製造方法の一工程を示す断面図(その1)。Sectional drawing which shows 1 process of the manufacturing method of the microneedle which concerns on embodiment (the 1). 実施形態に係るマイクロニードルの製造方法の一工程を示す断面図(その2)。Sectional drawing which shows 1 process of the manufacturing method of the microneedle which concerns on embodiment (the 2). 実施形態に係るマイクロニードルの製造方法の一工程を示す断面図(その3)。Sectional drawing which shows 1 process of the manufacturing method of the microneedle which concerns on embodiment (the 3). 実施形態に係るマイクロニードルの製造方法の一工程を示す断面図(その4)。Sectional drawing which shows 1 process of the manufacturing method of the microneedle which concerns on embodiment (the 4).

マイクロニードルにより薬物を添加して医療効果を発揮させるためには、マイクロニードルが皮膚を穿刺した際に、その先端部が表皮を貫通して真皮に到達し、真皮に薬物が所定量正確に供給され、先端部が基台部から短時間で切離されて、先端部に添加されている薬物が真皮を介して体内に吸収されることが必要である。
本発明に係るマイクロニードルはこれを容易に実現することが出来る。
In order to add a drug with a microneedle and exert a medical effect, when the microneedle punctures the skin, the tip of the microneedle penetrates the epidermis and reaches the dermis, and a predetermined amount of drug is accurately supplied to the dermis Therefore, it is necessary that the distal end portion is separated from the base portion in a short time, and the drug added to the distal end portion is absorbed into the body through the dermis.
The microneedle according to the present invention can easily realize this.

まず、図1を参照して、本発明の実施形態に係るマイクロニードルの構成を説明する。
図1において、マイクロニードル100は、先端部102と基台部104とを有している。先端部102は、鋭利な円錐形、基台部104は円錐台形であるが、円錐形、円錐台形に代えてそれぞれ角錐形、角錐台形としてもよい。
先端部102の高さHと基台部104の高さHとは、マイクロニードル100を皮膚に穿刺した際に先端部102が真皮内にとどまるのに十分な寸法となるように設計されている。先端部(先端部位)102と基台部(基台部位)104とは、肩部106において段差を有して結合されており、本発明においては、先端部位102と基台部位104とでその構成材料の材質を異ならせている。
First, with reference to FIG. 1, the structure of the microneedle which concerns on embodiment of this invention is demonstrated.
In FIG. 1, the microneedle 100 has a distal end portion 102 and a base portion 104. The tip portion 102 has a sharp conical shape, and the base portion 104 has a frustoconical shape. Instead of the conical shape and the frustoconical shape, a pyramid shape and a truncated pyramid shape may be used, respectively.
The height H 2 of the height H 1 and the base portion 104 of the tip 102 is designed microneedles 100 as the tip 102 when the puncture in the skin is sufficient size to stay within the dermis ing. The tip portion (tip portion) 102 and the base portion (base portion) 104 are joined at the shoulder 106 with a step, and in the present invention, the tip portion 102 and the base portion 104 are connected to each other. The materials of the constituent materials are different.

一例として、構成材料を生体内溶解性樹脂として、先端部位102には、ポリ乳酸、マルトース、コンドロイチン硫酸及びカルボキシメチルセルロースなどを素材としたものを用い、基台部位104には熱可塑性樹脂として、ポリカーボネート、ポリプロピレン、シクロオレフィンポリマー、シクロオレフィンコポリマー、ポリエチレンテレフタートまたはこれらの混合物を素材としたものを用いる。
また同一素材の構成材料を用いた場合でもその分子量を異なるようにして材質を変えても良い。例えば、構成材料をヒアルロン酸とした場合に、先端部位102のヒアルロン酸には、低分子量のものを用い、基台部位104のヒアルロン酸には高分子量のものを用いる。
As an example, the constituent material is a biosoluble resin, the tip portion 102 is made of polylactic acid, maltose, chondroitin sulfate, carboxymethyl cellulose, or the like, and the base portion 104 is a polycarbonate resin as a thermoplastic resin. , Polypropylene, cycloolefin polymer, cycloolefin copolymer, polyethylene terephthalate or a mixture thereof is used.
Even when the same constituent material is used, the material may be changed by changing the molecular weight. For example, when the constituent material is hyaluronic acid, the hyaluronic acid at the distal end portion 102 has a low molecular weight, and the hyaluronic acid at the base portion 104 has a high molecular weight.

このように構成材料を先端部位102と基台部位104とで材質を異ならせることで、肩部106における先端部位102と基台部位104との結合力が弱まり、マイクロニードル100が皮膚に穿刺された後に肩部106において先端部位102と基台部位104とが容易に切離され、先端部位102のみを皮膚の真皮内に残留させることが可能となる。そして、先端部位102の構成材料にのみ薬物108が含有されるようにしておけば、先端部位102の容量で定まる一定量の薬物108を正確に生体に投与することが可能になる。   Thus, by making the constituent materials different between the tip portion 102 and the base portion 104, the bonding force between the tip portion 102 and the base portion 104 in the shoulder portion 106 is weakened, and the microneedle 100 is punctured into the skin. After that, the tip portion 102 and the base portion 104 are easily separated from each other at the shoulder 106, and only the tip portion 102 can be left in the dermis of the skin. If the drug 108 is contained only in the constituent material of the distal end portion 102, a certain amount of the drug 108 determined by the volume of the distal end portion 102 can be accurately administered to the living body.

薬物108としては、現在、インスリンなどのペプチド・タンパク性医薬品を対象としている。なお、先端部102の先端角度θ、基台部104の先端側端部の角度θは共に14°未満に設定されている。14°以上では、マイクロニードル100を皮膚に穿刺した際に、先端部102が真皮へ到達し難くなるからである。
また、マイクロニードル100の構成材料は液体であり、成形時に水分を除去することにより固化される。
The drug 108 is currently targeted for peptide / protein drugs such as insulin. Note that the tip angle θ 1 of the tip portion 102 and the angle θ 2 of the tip side end portion of the base portion 104 are both set to be less than 14 °. This is because when the angle is 14 ° or more, the tip 102 does not easily reach the dermis when the microneedle 100 is punctured into the skin.
Moreover, the constituent material of the microneedle 100 is a liquid, and is solidified by removing moisture during molding.

次に図2、図3を参照して、図1で示すマイクロニードル100の使用方法について説明する。
図2において、マイクロニードル100を皮膚に穿刺すると、マイクロニードル100はその先端部102が皮膚組織を切開して侵入し、角質層Kを貫通して真皮Sへ到達する。その後、図2に示すように先端部102はすべて真皮Sの中まで侵入し、基台部104もその先端が角質層Kと真皮Sとの境界まで侵入する。
Next, a method of using the microneedle 100 shown in FIG. 1 will be described with reference to FIGS.
In FIG. 2, when the microneedle 100 is punctured into the skin, the tip 102 of the microneedle 100 invades the skin tissue, penetrates through the stratum corneum K, and reaches the dermis S. After that, as shown in FIG. 2, all the distal end portion 102 penetrates into the dermis S, and the distal end of the base portion 104 also penetrates to the boundary between the stratum corneum K and the dermis S.

この状態で所定時間放置すると、先端部(先端部位)102を構成している構成材料が溶け出して、真皮Sを介して生体に供給される。これに伴い、先端部位102の構成材料に含有されていた薬物108が生体に投与される。この場合、生体に投与される薬物108の量は、予め先端部位102の形状を定めておけば、常に一定量となる。
この状態で薬物108がすべて生体に投与されるまでマイクロニードル100を皮膚内に所定時間放置することも出来るが、仮にマイクロニードル100を矢印A方向に引き抜こうとすると、先端部位102と基台部位104との結合部位である肩部106において、切離され、先端部位102のみが図3に示すように真皮S内に残存する。従って薬物108の薬効は長期間に亘って効率的に発揮される。
If left in this state for a predetermined time, the constituent materials constituting the tip portion (tip portion) 102 are melted and supplied to the living body through the dermis S. Along with this, the drug 108 contained in the constituent material of the distal end portion 102 is administered to the living body. In this case, the amount of the drug 108 administered to the living body is always a constant amount if the shape of the distal end portion 102 is determined in advance.
In this state, the microneedle 100 can be left in the skin for a predetermined time until all of the drug 108 is administered to the living body. However, if the microneedle 100 is pulled out in the direction of arrow A, the distal end portion 102 and the base portion 104 will be removed. In the shoulder portion 106 which is a binding site to the dermis, it is cut off, and only the distal end portion 102 remains in the dermis S as shown in FIG. Therefore, the efficacy of the drug 108 is efficiently exhibited over a long period.

次に、図1に示す実施形態に係るマイクロニードル100の製造方法について図4〜図7を参照して説明する。
まず、図4に示すように、先端側に位置する先端部位102aと、基台側に位置する基台部位104aとを備えたマイクロニードルの鋳型100aを準備する。
この鋳型100aはレーザビームを用いて鋳型材料を直接レーザエッチングしたり、又はフォトリソグラフィーを用いた食刻技術により作製することができる。先端部位102aと基台部位104aの結合部位には段部106aが形成されている。
Next, a method for manufacturing the microneedle 100 according to the embodiment shown in FIG. 1 will be described with reference to FIGS.
First, as shown in FIG. 4, a microneedle mold 100a having a distal end portion 102a located on the distal end side and a base portion 104a located on the base side is prepared.
The mold 100a can be manufactured by directly laser-etching a mold material using a laser beam or by an etching technique using photolithography. A stepped portion 106a is formed at a joint portion between the distal end portion 102a and the base portion 104a.

次いで、図5に示すように、先端部位102a内を液状の第1構成材料102bで充填し、所定時間放置する。第1構成材料102bとして、例えば低分子量のヒアルロン酸を用いる。第1構成材料102bは段部106aに到達するまで充填し、この第1構成材料102b中に、薬物108、例えば、インスリンを所定量だけ含有させておく。   Next, as shown in FIG. 5, the inside of the tip portion 102a is filled with the liquid first constituent material 102b and left for a predetermined time. For example, low molecular weight hyaluronic acid is used as the first constituent material 102b. The first constituent material 102b is filled until it reaches the stepped portion 106a, and a predetermined amount of the drug 108, for example, insulin is contained in the first constituent material 102b.

第1構成材料102bを充填して固化が始まった段階で、基台部位104aに第1構成材料102bとは材質、即ち、成分又は材料が異なる液状の第2構成材料104bを図6に示すように充填し、所定時間放置し固化させ、段部106aにおいて第1構成材料102bと第2構成材料104bとを結合させる。
第2構成材料104bとしては、例えば、高分子量のヒアルロン酸を用いる。第2構成材料104b中には薬物108を含有させない。
As shown in FIG. 6, when the first constituent material 102 b is filled and solidification starts, the base part 104 a has a liquid second constituent material 104 b that is different from the first constituent material 102 b in material, that is, component or material. The first constituent material 102b and the second constituent material 104b are bonded at the stepped portion 106a.
As the second constituent material 104b, for example, high molecular weight hyaluronic acid is used. The drug 108 is not contained in the second constituent material 104b.

このようにしてマイクロニードル100が形成された段階で、図7に示すように矢印Bの方向に引き上げてこれを取り出す。
図4〜図7に示す製造工程では、マイクロニードルの鋳型100aにより、複数のマイクロニードル(図4〜図7では3個)を同時に製造しているが、単一のマイクロニードルずつでも製造することは出来る。
When the microneedle 100 is thus formed, it is pulled up in the direction of arrow B as shown in FIG.
In the manufacturing process shown in FIGS. 4 to 7, a plurality of microneedles (three in FIGS. 4 to 7) are manufactured at the same time by the microneedle mold 100a, but each single microneedle is manufactured. Can do.

100・・・・マイクロニードル
100a・・・マイクロニードルの鋳型
102・・・・先端部(先端部位)
102b・・・第1構成材料
104・・・・基台部(基台部位)
104b・・・第2構成材料
106・・・・肩部
108・・・・薬物
DESCRIPTION OF SYMBOLS 100 ... Microneedle 100a ... Microneedle mold 102 ... Tip part (tip part)
102b ... 1st constituent material 104 ... Base part (base part)
104b ... Second component material 106 ... Shoulder 108 ... Drug

Claims (5)

鋭利な先端を有する円錐形又は角錐形の先端部(102)と円錐台形又は角錐台形の基台部(104)とを備え、前記先端部(102)と前記基台部(104)とは、前記基台部(104)の肩部(106)において段差を有して結合されたマイクロニードル(100)において、
前記先端部(102)の前記先端から前記肩部(106)までの高さ(H)と前記基台部(104)の高さ(H)とは、前記マイクロニードル(100)を前記先端から皮膚に穿刺した際に、前記先端部(102)はすべて真皮内にとどまり、前記基台部(104)は、少なくとも前記肩部(106)が角質層と真皮との境界まで侵入するのに十分な寸法に設計され、
前記先端部(102)と前記基台部(104)とはその構成材料の材質を異にし、
前記先端部(102)の構成材料にのみ一定量の薬物(108)を含有させたことを特徴とするマイクロニードル。
A conical or pyramidal tip (102) having a sharp tip and a truncated cone or truncated pyramid base (104), wherein the tip (102) and the base (104) are: In the microneedle (100) coupled with a step at the shoulder (106) of the base (104),
The height (H 1 ) from the tip of the tip (102) to the shoulder (106) and the height (H 2 ) of the base (104) determine the microneedle (100) as described above. When the skin is punctured from the tip, all the tip (102) stays in the dermis, and at least the shoulder (106) penetrates to the boundary between the stratum corneum and the dermis in the base (104). Designed with sufficient dimensions,
The tip portion (102) and the base portion (104) are made of different materials.
A microneedle characterized by containing a fixed amount of a drug (108) only in the constituent material of the tip (102).
前記薬物(108)がペプチド・タンパク性医薬品であることを特徴とする請求項1に記載のマイクロニードル。   The microneedle according to claim 1, wherein the drug (108) is a peptide / protein drug. 前記先端部(102)の先端角度(θ)と、前記基台部(104)の先端側端部の角度(θ)とが共に14°未満に設定されていることを特徴とする請求項1又は2に記載のマイクロニードル。 The tip angle (θ 1 ) of the tip portion (102) and the angle (θ 2 ) of the tip side end portion of the base portion (104) are both set to be less than 14 °. Item 3. The microneedle according to item 1 or 2. 前記肩部(106)において、前記先端部(102)と前記基台部(104)とが容易に切離され、前記先端部(102)のみを皮膚の真皮内に残留させることを特徴とする請求項1乃至3のいずれかに記載のマイクロニードル。   In the shoulder (106), the distal end (102) and the base (104) are easily separated, and only the distal end (102) remains in the dermis of the skin. The microneedle according to any one of claims 1 to 3. 請求項1乃至4に記載のマイクロニードル(100)の製造工程が、
a:鋳型材料への直接レーザエッチング又はフォトリソグラフィーを用いた食刻技術により、先端側に位置する先端部位(102)と基台側に位置する基台部位(104)とを備え、
前記先端部位(102)と前記基台部位(104)とは、前記基台部位(104)の肩部(106)において段差を有して結合されたマイクロニードルパターンの反転形状を有する鋳型を作製する工程と;
b:前記先端部位(102)に一定量の薬物(108)を含有した液状の第1構成材料で前記肩部(106)に到達するまで充填し、所定時間放置して固化を開始させる工程と;
c:前記基台部位(104)に前記第1構成材料とは材質が異なる液状の第2構成材料を充填し、所定時間放置し、前記先端部位(102)と前記基台部位(104)とを前記肩部(106)において結合させる工程と;
d:前記第1構成材料と前記第2構成材料とを固化させてマイクロニードルを形成する工程と;
e:形成された前記マイクロニードルを前記鋳型から取り出す工程と;
を具備したことを特徴とするマイクロニードルの製造方法。
The manufacturing process of the microneedle (100) according to claim 1 to 4,
a: It comprises a tip portion (102) located on the tip side and a base portion (104) located on the base side by an etching technique using direct laser etching or photolithography on the mold material,
The tip part (102) and the base part (104) are produced as a mold having a reversal shape of a microneedle pattern joined with a step at the shoulder part (106) of the base part (104). A process of performing;
b: filling the tip portion (102) with a liquid first constituent material containing a certain amount of drug (108) until it reaches the shoulder (106) and leaving it for a predetermined time to start solidification; ;
c: Filling the base part (104) with a liquid second constituent material, which is different from the first constituent material, and letting it stand for a predetermined time, and the tip part (102) and the base part (104) Bonding at the shoulder (106);
d: a step of solidifying the first constituent material and the second constituent material to form a microneedle;
e: removing the formed microneedle from the mold;
A method for producing a microneedle, comprising:
JP2017235882A 2017-12-08 2017-12-08 Microneedle and manufacturing method thereof Active JP6681378B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017235882A JP6681378B2 (en) 2017-12-08 2017-12-08 Microneedle and manufacturing method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017235882A JP6681378B2 (en) 2017-12-08 2017-12-08 Microneedle and manufacturing method thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017018802 Division 2017-02-03

Publications (2)

Publication Number Publication Date
JP2018122081A true JP2018122081A (en) 2018-08-09
JP6681378B2 JP6681378B2 (en) 2020-04-15

Family

ID=63109948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017235882A Active JP6681378B2 (en) 2017-12-08 2017-12-08 Microneedle and manufacturing method thereof

Country Status (1)

Country Link
JP (1) JP6681378B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200090447A (en) * 2019-01-21 2020-07-29 주식회사 비안랩 Micro needle patch and manufacturing method thereof
JP2022520165A (en) * 2019-01-30 2022-03-29 ラファス カンパニー リミテッド Minimal moist skin biopsy method using microneedle patch
CN116474254A (en) * 2023-05-06 2023-07-25 上海加以科技有限公司 Hierarchical microneedle patch and processing method
CN118370924A (en) * 2023-01-16 2024-07-23 深圳青澜生物技术有限公司 Microneedle array and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003238347A (en) * 2002-02-18 2003-08-27 Nano Device & System Research Inc Functional micropile and method for producing the same
US20050065463A1 (en) * 2003-09-18 2005-03-24 Nano Device And System Research Inc. Applicator for applying functional substances into human skin
JP2012196426A (en) * 2010-09-29 2012-10-18 Fujifilm Corp Needle array transdermal absorption sheet and method for manufacturing needle array transdermal absorption sheet
US20140005606A1 (en) * 2012-06-29 2014-01-02 Mei-Chin Chen Embeddable micro-needle patch for transdermal drug delivery and method of manufacturing the same
JP2016511014A (en) * 2012-12-21 2016-04-14 コリウム インターナショナル, インコーポレイテッド Microarrays for delivering therapeutic agents and methods of use
WO2016114213A1 (en) * 2015-01-13 2016-07-21 凸版印刷株式会社 Transdermal administration device
WO2016149152A1 (en) * 2015-03-13 2016-09-22 The University Of North Carolina At Chapel Hill Polymeric microneedles and rapid additive manufacturing of the same
JP2018079127A (en) * 2016-11-17 2018-05-24 Aof株式会社 Micro needle

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003238347A (en) * 2002-02-18 2003-08-27 Nano Device & System Research Inc Functional micropile and method for producing the same
US20050065463A1 (en) * 2003-09-18 2005-03-24 Nano Device And System Research Inc. Applicator for applying functional substances into human skin
JP2012196426A (en) * 2010-09-29 2012-10-18 Fujifilm Corp Needle array transdermal absorption sheet and method for manufacturing needle array transdermal absorption sheet
US20140005606A1 (en) * 2012-06-29 2014-01-02 Mei-Chin Chen Embeddable micro-needle patch for transdermal drug delivery and method of manufacturing the same
JP2016511014A (en) * 2012-12-21 2016-04-14 コリウム インターナショナル, インコーポレイテッド Microarrays for delivering therapeutic agents and methods of use
WO2016114213A1 (en) * 2015-01-13 2016-07-21 凸版印刷株式会社 Transdermal administration device
WO2016149152A1 (en) * 2015-03-13 2016-09-22 The University Of North Carolina At Chapel Hill Polymeric microneedles and rapid additive manufacturing of the same
JP2018079127A (en) * 2016-11-17 2018-05-24 Aof株式会社 Micro needle

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200090447A (en) * 2019-01-21 2020-07-29 주식회사 비안랩 Micro needle patch and manufacturing method thereof
KR102263673B1 (en) * 2019-01-21 2021-06-18 주식회사 제이앤제이코스텍 Micro needle patch and manufacturing method thereof
JP2022520165A (en) * 2019-01-30 2022-03-29 ラファス カンパニー リミテッド Minimal moist skin biopsy method using microneedle patch
JP7272711B2 (en) 2019-01-30 2023-05-12 ラファス カンパニー リミテッド Minimal invasive skin biopsy method using microneedle patch
CN118370924A (en) * 2023-01-16 2024-07-23 深圳青澜生物技术有限公司 Microneedle array and preparation method thereof
WO2024152796A1 (en) * 2023-01-16 2024-07-25 深圳青澜生物技术有限公司 Microneedle array and preparation method therefor
CN116474254A (en) * 2023-05-06 2023-07-25 上海加以科技有限公司 Hierarchical microneedle patch and processing method

Also Published As

Publication number Publication date
JP6681378B2 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
JP6681378B2 (en) Microneedle and manufacturing method thereof
US11052231B2 (en) Microarray for delivery of therapeutic agent and methods of use
JP6370296B2 (en) Microneedle array and microneedle array manufacturing method
KR101610598B1 (en) FLEXIBLE MICRONEEDLE FOR DENTAL MATERIAL DELIVERY AND THE MANUFACTURING METHOD Of THE SAME
JP6558812B2 (en) Microneedle and microneedle patch
US20090234301A1 (en) Microneedle array and method for producing microneedle array
JP6709562B2 (en) Method of manufacturing microneedle array coated with drug
KR101746024B1 (en) Micro needle which coated porous coating layer and manufacturing method of this and micro needle patch using the micro needle
JP6421393B1 (en) Manufacturing method of microneedle
WO2011043085A1 (en) Stamper for microneedle sheet, method for manufacturing the stamper, and method for manufacturing microneedle using the stamper
JP2016511014A5 (en)
JP2011005245A (en) Method for producing pinholder-shaped microneedle, and microneedle
HK1205024A1 (en) Microneedle and microneedle array
KR200479627Y1 (en) Patch with micro-needles
WO2008015782A1 (en) Microneedle patch and process for producing the same
US20210121673A1 (en) Micro-needle and method of manufacture
JP2005021678A (en) Pad base for percutaneous admistration and its manufacturing method
KR101868872B1 (en) Micro-needle and manufacturing method thereof
JP6003338B2 (en) Acicular package
JPWO2019059265A1 (en) Microneedle sheet and method for manufacturing microneedle sheet
US20210322746A1 (en) Skin quality-improving sheet
KR102836377B1 (en) Method for manufacturing microneedle patch
KR101698846B1 (en) Method and apparatus for manufacturing micro needle, micro needle and computer readable recording medium
Korkmaz et al. Dissolvable and coated microneedle arrays: design, fabrication, materials and administration methods
Longo et al. Silicon microneedles for transdermal applications by electrochemical micromachining technology

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181030

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190619

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200323

R150 Certificate of patent or registration of utility model

Ref document number: 6681378

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250